Melema Pharma Gmbh

Cytavis Biopharma Gmbh

Other

Madaus Ag

Viscum Ag

Hans Lentzen

Klaus Witthohn

Holger Zinke

Axel Baur

J&uuml;rgen Eck

Ulrich Mengs

Hilmar Stolte

Karl-Peter Odenthal

Jurgen Eck

Methods of treating a brain tumor by administering a drug containing recombinant mistletoe lectin are described. The recombinant mistletoe lectin can be a mistletoe lectin A-chain, a mistletoe lectin B-chain, or a combination thereof. Brain tumors that can be treated by the method described include primary brain tumours, gliomas, glioblastomas, meningiomas and pituitary adenomas.

Medicament containing recombinant mistletoe lectins for the treatment of brain tumors

An antiviral agent containing recombinant mistletoe lectins for treating virus infections and a medicament and/or pharmaceutical composition for treating virus infections are described. Recombinant mistletoe lectin polypeptides can be a mistletoe lectin A-chain, as well as parts or fragments of the mistletoe lectin A-chain. The antiviral agent can be used for any number of virus infections, such as Herpes simplex, adenovirus, poliovirus, and poxvirus. Also, the antiviral agent can be used for skin virus warts, anogenital warts, mucous membrane warts and malignant tumors such as cervical cancer, penis and vulvar cancer.

Antiviral agent comprising recombinant mistletoe lectins

A drug and/or pharmaceutical composition comprising recombinant mistletoe lectins for treating metastatic tumors, including malignant melanoma such as stage IV malignant melanoma, and use of said drug, particularly in select patient populations, are described. Recombinant mistletoe lectin polypeptides can be a mistletoe lectin A-chain or fragments thereof. Alternatively, the recombinant mistletoe lectin polypeptides can be mistletoe lectin B-chain or fragments thereof. The drug can be used for the treatment of stages III and IV of a metastatic tumor or skin cancer, as well as to treat non-responders and therapeutic failures of a standard tumor therapy. The drug can be used in a dosage in a range of 3-7 ng recombinant mistletoe lectin per kg body weight. The dosage of the recombinant mistletoe lectin can also be 200-500 ng, independently of body weight. The drug can be administered once a week, or more frequently.

Drug containing recombinant mistletoe lectins for treating malignant melanoma

The invention relates to nucleic acid molecules encoding preproproteins having after maturation the biological activity of the mistletoe lectin dimer, to vectors comprising these nucleic acid molecules, to hosts transformed with said vectors and to polypeptides and/or polypeptide dimers which are encoded by these nucleic acid molecules. The polypeptides and/or polypeptide dimers of the invention are widely therapeutically applicable. Thus, the present invention further relates to immunotoxins as well as to pharmaceutical compositions that contain the polypeptides and/or the polypeptide dimers of the invention. Additionally, the invention relates to diagnostic compositions comprising the nucleic acid molecules of the invention, the polypeptides and/or the polypeptide dimers of the invention and/or primers which hybridize specifically to the nucleic acid molecules of the invention. Finally, the invention relates to plant protective agents comprising the polypeptides of the invention and/or the polypeptide dimers of the invention.

Recombinant mistletoe lectin (rML)

The present invention is concerned with the use of flavolignans as adjuvants in the case of chemotherapeutic tumour treatment and for the protection of cells in the urogenital region.

Growing community of inventors

Rösrath, Germany

Hans Lentzen